Shots:
- Minaris is advancing its dual-business strategy through specialized Advanced Therapies and Advanced Testing units, enabling sponsors to streamline development, manufacturing, biosafety testing, and commercialization within one integrated global organization.
- Minaris is focused on solving key cell & gene therapy manufacturing challenges by reducing variability, accelerating tech transfer, improving “first time right” execution, and lowering cost of goods through scalable and commercially viable manufacturing approaches.
- PharmaShots welcomes Dr. Orla Cloak, CEO of Minaris, who shares insights on integrated advanced therapy manufacturing, multimodality testing, regulatory readiness, and the evolving strategies shaping the future of cell & gene therapy commercialization.
Saurabh: Welcome to PharmaShots Viewpoints! Minaris brings together advanced therapy manufacturing and advanced testing capabilities. What is the defining opportunity shaping this next phase of the company’s journey?
Orla: The defining opportunity is to support innovators with capabilities across two distinct business units: Advanced Therapies, a pure-play CDMO focused on cell and gene therapy, and Advanced Testing, which provides biosafety testing, viral clearance, potency assays, and broader multimodal testing services. By offering these capabilities through a single, integrated company, Minaris can help simplify the path from innovation through commercialization, while maintaining the specialized expertise each business requires. Ultimately, our focus is on helping sponsors advance complex therapies safely, reliably, and efficiently toward patients.
Saurabh: How does this combined business model strengthen Minaris’ position as a global partner for innovators?
Orla: Minaris offers sponsors access to both specialized manufacturing expertise and advanced testing capabilities within one organization. Our Advanced Therapies business brings a global manufacturing footprint, including locations on the East Coast of the U.S., in Germany, and in Japan, while our Advanced Testing business operates a center of excellence in Philadelphia. This model allows each business unit to maintain focus and technical depth, while giving customers the benefit of a partner that understands the broader development, manufacturing, quality, and testing requirements needed to move advanced therapies and biologics forward.
Saurabh: What strategic priorities are guiding Minaris as it advances both lines of business?
Orla: Our priorities are focused on strengthening the company’s foundation, supporting operational excellence, and aligning around initiatives that matter most to customers and patients. These include reducing the cost of goods of cell and gene therapies, driving “first time right” execution, innovating to enable customers, and regulatory expertise to enable progress with confidence. Across both business units, we are focused on building strong partnerships, maintaining quality as a core operating principle, and ensuring that our teams have the expertise and agility needed to support complex programs from development through commercialization.
Saurabh: What role does partnership play in Minaris’ approach to working with sponsors?
Orla: Partnership is central to how we work. In advanced therapies and testing, the technical and regulatory complexity is too significant for a purely transactional service-provider relationship. Sponsors need partners who understand the science, support process development, anticipate quality and regulatory requirements, and help solve operational challenges. We work closely with sponsor teams to identify risks, improve processes, and build strategies that support long-term success. Our goal is to help innovators move therapies forward safely, reliably, efficiently, and with patients always in focus.
Saurabh: In cell and gene therapy manufacturing, what differentiates Minaris’ Advanced Therapies CDMO business?
Orla: In cell and gene therapy, the industry has moved beyond a capacity conversation. It is now about capability. These therapies are living, highly complex, and often patient-specific products with unique technical, regulatory, and supply chain demands. Minaris brings more than 25 years of experience in cell and gene therapy, with depth across both autologous and allogeneic programs. We understand the complexity of the development-through-commercialization process, and we work closely with sponsors to build robust GMP processes, reduce variability, improve efficiency, and support scalable manufacturing strategies.
Saurabh: What are the biggest manufacturing challenges sponsors face as cell and gene therapies move toward late-stage development and commercialization?
Orla: The biggest challenges are variability, speed, quality, and cost of goods. Many early-generation processes include manual steps that can introduce variability and operator dependency. Sponsors are also under pressure to accelerate tech transfer and scale-up in parallel with clinical development rather than sequentially. For autologous therapies, vein-to-vein time is especially critical. At the same time, sponsors need processes that are reproducible, inspection-ready, and globally scalable. The focus is shifting toward earlier process understanding, stronger control strategies, and manufacturing models that can support commercial viability.
Saurabh: Cost of goods remains a central concern in advanced therapies. How is Minaris helping sponsors improve scalability and affordability?
Orla: The cost of goods is one of the key barriers to broader patient access, and addressing it requires close collaboration between the sponsor and the CDMO partner. We work with sponsors by bringing together technical, operational, and quality experts to map the process, identify inefficiencies, reduce variability, and improve manufacturability. Platform thinking is important, but it must remain flexible because one size does not fit all. In some collaborations, this approach has helped identify cost-of-goods reductions of 60–70%, while in other cases it has supported reduced variability and strong batch success rates.
Saurabh: How should sponsors think about tech transfer and scale-up for cell and gene therapy programs?
Orla: Sponsors increasingly need tech transfer and scale-up to happen earlier and more efficiently, often in parallel with clinical development. That requires cleaner, more standardized transfers, stronger documentation, and less reliance on tribal knowledge. Manufacturing partners need to absorb processes quickly while maintaining adaptability and quality. We are seeing more emphasis on platform approaches, digital documentation, and global strategy because these therapies often need to move across sites, suppliers, and regulatory environments. Early process understanding is critical to reducing risk later.
Saurabh: Turning to Advanced Testing, how is Minaris improving speed, reliability, and quality for customers?
Orla: Our Advanced Testing business has a center of excellence in Philadelphia with strong expertise in biosafety testing, viral clearance, and potency assays. The focus is on providing predictable, consistent, scientifically rigorous results while making it easier for customers to do business with us. We are streamlining the customer journey from sample receipt through result delivery by improving systems, infrastructure, workflows, and customer-facing tools. We are also focused on shortening turnaround times through innovation and next-generation technologies, while ensuring that quality enables progress rather than becoming a bottleneck.
Saurabh: Regulatory requirements for biologics, vaccines, and advanced therapies continue to evolve. How does Minaris help sponsors maintain confidence in timelines and results?
Orla: Regulatory confidence is built through expertise, proven science, and continuous engagement with industry direction. Many experts within our Advanced Testing business have more than 20 years of experience in developing, validating, and applying assays, as well as interacting with regulators and customers. We continuously update our capabilities as expectations evolve, including next-generation sequencing, recombinant endotoxin approaches, rapid sterility, ultra-rapid sterility, and rapid mycoplasma testing. Our goal is to remain inspection-ready, scientifically rigorous, and aligned with both current and future regulatory requirements.
Saurabh: Advanced Testing supports multiple modalities beyond cell and gene therapy. How does this broader scope benefit customers?
Orla: While our Advanced Therapies CDMO business is focused on cell and gene therapy, our Advanced Testing business is multimodality. It supports cell and gene therapies, biologics, vaccines, and other modalities through capabilities such as biosafety testing, viral clearance, and potency assays. That broader scope allows us to support customers across different product types while applying deep scientific and regulatory expertise. It also helps sponsors work with a testing partner that understands evolving modality-specific expectations and the importance of reliable, timely results.
Saurabh: Looking ahead, where do you see the strongest growth opportunities across Advanced Therapies and Advanced Testing?
Orla: The strongest opportunity is in helping innovators move faster and more reliably from development to commercialization. In Advanced Therapies, that means solving manufacturing complexity, improving process robustness, and supporting commercially viable cost structures. In Advanced Testing, it means using scientific and technological innovation to provide faster, more reliable, and more predictive testing solutions. Across both businesses, our goal is to remove bottlenecks, strengthen quality, and help bring important therapies to patients safely, efficiently, and at scale.
About Dr. Orla Cloak
Dr. Orla Cloak is the CEO of Minaris, a global partner specializing in cell therapy CDMO services and multimodality testing. With more than 25 years of experience in cell therapy manufacturing, Dr. Cloak brings extensive expertise in advancing innovative therapies from development to commercialization. Under her leadership, Minaris continues to support advanced therapy developers worldwide through its proven capabilities, including the release of over 7,500 GMP batches and comprehensive analytical and biosafety testing services across the full product lifecycle. Since joining the company in July 2025, Dr. Cloak has been driving Minaris through its next phase of strategic growth and global expansion.
